Today 4 Companies Raised $100 Million.
2070 Health, GetHarley, Significo, and Cellusion Announced Fundraising Rounds.
Interested in human due diligence services for your investment firm? Visit our website to learn more and connect with us today!
Deal #1: 2070 Health, a venture studio, secures $30 million funding to support the establishment of healthtech companies.
About:
2070 Health has a primary objective of improving accessibility and affordability in the realm of high-quality healthcare. As a venture studio, they specialize in creating patient-centric healthcare firms from the ground up, bringing together innovative concepts, accomplished founders, and a robust innovation platform. Through their endeavors, 2070 Health seeks to revolutionize the healthcare industry by making it more accessible, convenient, and cost-effective for individuals from all walks of life.
Funding Round Info:
2070 Health, a healthcare venture studio, has successfully raised $30 million in funding from W Health Ventures, a healthcare-focused VC fund. The raised capital will be used to establish the 2070 Health platform and support the growth of newly launched healthcare companies. Founded in October 2022 by Pankaj Jethwani, 2070 Health aims to provide a platform for founders to test, launch, and iterate on their healthcare ideas in a rapid and efficient manner. Within a span of nine months, the studio has already launched three companies: ElevateNow, Nivaan Care, and Reveal HealthTech. Building healthcare companies in India poses unique challenges, and 2070 Health is actively addressing them. With the secured funding, the studio is well-positioned to further its mission of fostering innovation in the healthcare sector.
Deal #2: Skincare Telehealth and Consultation Platform, GetHarley, Successfully Raises $52 Million in Funding.
About:
GetHarley is revolutionizing the skincare landscape by prioritizing knowledge over hype. As the pioneering telehealth platform, we connect individuals with experienced clinicians to unlock personalized insights and recommendations for a wide range of skincare concerns. From addressing teenage acne to embracing graceful aging, GetHarley offers comprehensive end-to-end care tailored to every skin type. Founded in 2019 and headquartered in London, England, GetHarley has emerged as a trusted resource for individuals seeking informed skincare decisions. Our platform is designed to empower users with the knowledge and guidance needed to make informed choices about their skincare regimen. With GetHarley, discover a new level of personalized skincare that combines expert advice, advanced telehealth technology, and a vast array of treatments and products. Say goodbye to skincare uncertainties and embrace a confident and informed approach to achieving your skin goals with GetHarley.
Funding Round Info:
Skincare telehealth and consultation platform, GetHarley, has successfully raised $52 million in a recent funding round. The funding was led by existing investor Index Ventures, and other participants included Headline, Visionaries Club, and Village Global. GetHarley offers a unique approach by connecting consumers with skincare clinicians and curated skincare products. With a myriad of skincare products available in the market, GetHarley aims to simplify the selection process by leveraging qualified clinicians to recommend personalized skincare plans. Having previously raised approximately $15 million in funding, GetHarley has experienced notable growth since its inception four years ago. The platform boasts around 100,000 active users and has built a team of 70 members, which is expected to double in size over the coming year.
Deal #3: Significo Raises $12 Million in Series A Funding to Transform Personalized Health Recommendations and Bolsters Leadership Team.
About:
Significo, a company established in 2014, specializes in delivering AI-based individualization to users on a large scale. Their innovative approach allows organizations to provide highly personalized experiences to their users without the need for an in-house Advanced Data team. Significo leverages advanced technology and sophisticated algorithms to enable businesses to tap into the potential of AI and unlock the benefits of individualized experiences. By partnering with Significo, organizations can seamlessly integrate AI-driven individualization into their operations, saving valuable time and resources that would otherwise be spent on building and managing an internal Advanced Data team. With Significo's expertise and scalable solutions, businesses can enhance customer engagement and satisfaction through personalized experiences. By focusing on innovation and delivering effective AI-based individualization, Significo has established itself as a reputable player in the industry, helping businesses provide exceptional personalized experiences to their users.
Funding Round Info:
Significo, a trusted provider of secure and reliable digital health solutions, celebrates the successful closure of its Series A funding round with an impressive $12 million investment. This funding infusion solidifies Significo's commitment to scaling personalized health recommendations as a service, amplifying its impact in the digital health industry. The funding round was led by esteemed investor Doug Blough, a long-standing advocate of founders Rick McCartney and Chris Koha. The participation of such a respected investor marks a significant milestone in Significo's growth journey. With this financial backing, the company is poised to enhance its offerings and deliver a more human-centered experience in the digital health space. Recognizing the criticality of a strong and talented team, Significo has strategically welcomed key executives who will bolster the company's expansion and innovation efforts. Notably, Michael Robin joins as VP of Marketing, bringing valuable expertise, while Gary Rust assumes the role of Executive VP of Sales, contributing his extensive experience. Additionally, Daniel Schuster joins as the Director of Financial Planning and Analysis, ensuring robust financial management. With these accomplished individuals and other additions to their US-based team, Significo is well-positioned for continued success and plans to further expand its workforce in the coming year. These developments underline Significo's dedication to revolutionizing the digital health landscape, empowering individuals with personalized health recommendations, and fostering innovation through a strengthened leadership team.
Deal #4: Cellusion Successfully Raises 2.83 Billion Yen (21 Million USD) in Series C Funding Round.
About:
Cellusion, a pioneering regenerative medicine startup that emerged from Keio University, is driven by a powerful mission to provide groundbreaking therapies for individuals suffering from bullous keratopathy. Leveraging their innovative iPS cell-origin corneal endothelial cells mass culture system, Cellusion aims to transform the treatment landscape for these patients. Bullous keratopathy is a condition characterized by the dysfunction of corneal endothelial cells, leading to impaired vision and discomfort. Cellusion's cutting-edge approach harnesses the potential of induced pluripotent stem (iPS) cells to culture corneal endothelial cells on a large scale, enabling the development of novel therapies for this debilitating condition. With a firm commitment to advancing regenerative medicine, Cellusion is at the forefront of research and development, dedicated to delivering transformative solutions for bullous keratopathy patients. Through their groundbreaking efforts, they seek to provide new hope and improved quality of life for those affected by this condition.
Funding Round Info:
Cellusion Inc., headquartered in Tokyo and led by CEO Shin Hatou, has successfully completed its Series C financing round, raising a total of 2.83 billion yen (21 million USD). The funding round saw participation from several new investors, including JIC Venture Growth Investments Co., Ltd., NISSAY CAPITAL Co., Ltd., SPARX Asset Management Co., Ltd. (Mirai Creation Fund III), Axil Capital Partners II LLP, Nikon-SBI Innovation Fund, and AIS CAPITAL LIMITED. Additionally, existing investors such as The University of Tokyo Edge Capital Partners Co., Ltd., DBJ Capital Co., Ltd., SMBC Venture Capital Co., Ltd., and Gemseki Inc. also contributed to the financing round. With the successful Series C funding, Cellusion has now raised a total of 4.5 billion yen (33 million USD) to date, reflecting the confidence and support of investors in the company's vision and growth potential.
Interested in human due diligence services for your investment firm? Visit our website to learn more and connect with us today!